# Deven Chauhan

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/deven-chauhan/

## Facts

| Field | Value |
| --- | --- |
| Citations | 356 |
| Field | Systemic Lupus Erythematosus Research |
| h-index | 9 |
| i10-index | 9 |
| OpenAlex ID | https://openalex.org/A5017556545 |
| ORCID iD | 0000-0002-7237-3805 |
| Works | 24 |

## Researcher papers

- [Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial](https://scholariq.org/papers/safety-and-efficacy-of-ozanezumab-in-patients-with-amyotrophic-lateral-sclerosis/)
- [Factors affecting the uptake of new medicines in secondary care a literature review](https://scholariq.org/papers/factors-affecting-the-uptake-of-new-medicines-in-secondary-care-a-literature/)
- [Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus](https://scholariq.org/papers/impact-of-belimumab-on-organ-damage-in-systemic-lupus-erythematosus/)
- [A forgotten aspect of the NICE reference case: an observational study of the health related quality of life impact on caregivers of people with multiple sclerosis](https://scholariq.org/papers/a-forgotten-aspect-of-the-nice-reference-case-an-observational-study-of-the/)
- [Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials](https://scholariq.org/papers/attainment-of-remission-and-low-disease-activity-after-treatment-with-belimumab/)
- [Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks](https://scholariq.org/papers/belimumab-versus-anifrolumab-in-adults-with-systemic-lupus-erythematosus-an/)
- [Exploration of the difference in results of economic submissions to the National Institute of Clinical Excellence by manufacturers and assessment groups](https://scholariq.org/papers/exploration-of-the-difference-in-results-of-economic-submissions-to-the-national/)
- [Patient Reported Outcomes Instruments in Schizophrenia: A Review of Psychometric Properties](https://scholariq.org/papers/patient-reported-outcomes-instruments-in-schizophrenia-a-review-of-psychometric/)
- [Development, psychometric evaluation and cognitive debriefing of the rheumatoid arthritis symptom and impact questionnaire (RASIQ)](https://scholariq.org/papers/development-psychometric-evaluation-and-cognitive-debriefing-of-the-rheumatoid/)
- [A qualitative exploration of the patient experience of erosive and non-erosive hand osteoarthritis](https://scholariq.org/papers/a-qualitative-exploration-of-the-patient-experience-of-erosive-and-non-erosive/)
- [Patient-reported outcome measures for lupus nephritis: content validity of LupusQoL and FACIT-Fatigue](https://scholariq.org/papers/patient-reported-outcome-measures-for-lupus-nephritis-content-validity-of/)

## Researcher topics

- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Osteoarthritis Treatment and Mechanisms](https://scholariq.org/topics/osteoarthritis-treatment-and-mechanisms/)
- [Multiple Sclerosis Research Studies](https://scholariq.org/topics/multiple-sclerosis-research-studies/)
- [Atherosclerosis and Cardiovascular Diseases](https://scholariq.org/topics/atherosclerosis-and-cardiovascular-diseases/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.